Browse the evidence

Dual-agonists (GLP-1R/GIPR) and tri-agonists (GLP-1R/GIPR/GCGR) provide superior weight loss and cardiometabolic risk factor improvement (blood pressure, lipids) compared to GLP-1RAs alone, though their direct impact on hard cardiovascular outcomes (MACE) is still under investigation.

Newer medications like Tirzepatide (a dual agonist) may offer greater weight loss and improvements in blood pressure and cholesterol than older GLP-1 drugs. However, long-term data on whether this translates to fewer heart attacks or strokes is still being collected. If standard GLP-1s are not achieving your metabolic goals, discuss these newer options with your doctor.

Lifestyle modification, specifically caloric restriction and specific diets (e.g., Mediterranean, low-carbohydrate), reduces body weight and improves insulin resistance and hepatic steatosis, but its efficacy is moderate and less sustainable than GLP-1RA.

Losing just 5% of your body weight through caloric restriction can significantly improve insulin sensitivity and reduce liver fat by up to 40%. While lifestyle changes are the foundation of treatment, they often result in moderate weight loss compared to medications like GLP-1RA. Combining caloric reduction with exercise is effective, but maintaining this long-term is challenging, which is why pharmacological support is often needed for significant, sustained results.

GLP-1 receptor agonists improve hepatic steatosis and MASH resolution primarily through weight loss and direct inhibition of hepatic de novo lipogenesis.

GLP-1 agonists like semaglutide and liraglutide are effective treatments for MASH, achieving resolution in a significant portion of patients. They work by reducing liver fat through both weight loss and direct metabolic effects. Expect potential gastrointestinal side effects, which are usually manageable.

In real-world clinical practice, semaglutide produces attenuated weight loss (average 4.44%) compared to clinical trials, with diabetes mellitus diagnosis significantly reducing efficacy while linaclotide use and prediabetes are associated with enhanced weight loss.

If you are taking semaglutide in a standard clinical setting, expect an average weight loss of around 4-5% over a year, which is less than the 10-15% often cited from clinical trials. This difference is largely due to the lack of intensive lifestyle counseling provided in routine care. If you have diabetes, your weight loss may be further reduced, whereas having prediabetes or taking linaclotide might actually help you lose more weight.

Concomitant use of linaclotide is associated with significantly greater weight loss in patients taking semaglutide, whereas diabetes mellitus and dulaglutide use are associated with reduced efficacy.

If you are taking semaglutide, your other medications matter. Taking linaclotide (for constipation/IBS) is associated with better weight loss results, while taking diabetes medications like dulaglutide or metformin, or having a diabetes diagnosis, is associated with less weight loss. This suggests that your specific health profile and other drugs significantly influence semaglutide's effectiveness.

Anti-obesity medications (AOMs) including GLP-1 receptor agonists (liraglutide, semaglutide) and other agents (naltrexone-bupropion, phentermine-topiramate, orlistat) are significantly underutilized in clinical practice, with only 8% of eligible patients receiving a prescription and 4.4% filling it.

If you have obesity (BMI ≥30) and are interested in anti-obesity medications (AOMs) like GLP-1 agonists (e.g., semaglutide, liraglutide), be aware that access is heavily restricted by insurance type and demographics. In this study, only 8% of eligible patients got a prescription, and 4.4% filled it. If you are insured by Medicaid, Medicare, or are a minority, you face significantly lower odds of receiving these medications. Discuss these barriers with your provider and advocate for coverage options, as private insurance offers better access than public programs.

Oral semaglutide at 50 mg once daily achieves significantly greater HbA1c reduction (2.1%) and weight loss (9.8%) compared to the approved 14 mg dose, with higher discontinuation rates due to gastrointestinal adverse events.

If you have Type 2 Diabetes and struggle with blood sugar or weight, oral semaglutide 50mg is a potent non-injectable option. It works better than the standard 14mg dose, lowering HbA1c by 2.1% and causing nearly 10% weight loss. However, be prepared for potential stomach issues like nausea, which are common but usually mild. Take it on an empty stomach with a small sip of water as directed.

Short-term (10-day) time-restricted eating (8-hour window) does not impair daily myofibrillar protein synthesis rates compared to an extended 12-hour eating window when protein intake is matched.

If you are an overweight or obese male who exercises recreationally, switching to an 8-hour eating window (e.g., 10 AM to 6 PM) for 10 days will not hurt your muscle protein synthesis, provided you eat the same amount of protein (1g/kg) as you would over a longer period. Focus on hitting your daily protein goal rather than worrying about the clock.

Short-term time-restricted eating (8-hour window) improves 24-hour glucose homeostasis (reduced area under the curve) compared to an extended 12-hour eating window, despite identical food intake.

Compressing your eating window to 8 hours (e.g., 10 AM to 6 PM) can significantly improve your daily blood glucose control, even if you eat the exact same amount of food as you would over 12 hours. This is achieved by shifting meal times to delay breakfast and finish dinner earlier, which helps manage glucose spikes.

Supplementation with 15g/day of specific bioactive collagen peptides (CP) during 15 weeks of resistance training significantly increases skeletal muscle volume (hypertrophy) compared to placebo, without enhancing maximum strength gains.

If you are doing resistance training, taking 15g of specific collagen peptides daily may help you build more muscle mass than training alone, particularly in the quadriceps. However, do not expect this to make you stronger faster; your strength gains will likely be similar to those achieved with a placebo. Focus on the structural benefits for tissue health rather than immediate power output.

Processing and cooking methods that reduce antinutrients, denature proteins, and reduce food particle size improve dietary protein quality by increasing essential amino acid (EAA) digestibility and bioavailability.

Don't fear processing plant proteins. Cooking beans, lentils, and grains, or using protein isolates/powders, often makes the protein more digestible and bioavailable than eating them raw or in their whole, unprocessed form. This is especially important if you rely on plant-based proteins to meet your daily needs.

Orforglipron, an oral non-peptide GLP-1 receptor agonist, produces significant, dose-dependent weight loss (8.5–8.8%) in adults with obesity at doses of 24–36 mg/day, with gastrointestinal side effects being the primary limiting factor.

Take orforglipron once daily. Start at a low dose (6-9 mg) and increase to 12 mg, then to 24-36 mg as tolerated. Expect 8-9% body weight loss over 6 months. Manage nausea by titrating slowly.

Dual agonists of GLP-1 and glucagon (GCGR) or GIP receptors provide greater weight loss and broader metabolic benefits than mono-agonists, potentially addressing treatment barriers like cost and access by treating non-cardiometabolic complications.

If you have obesity, especially with related conditions like diabetes or fatty liver, newer dual-agonist medications (like tirzepatide) may offer significantly greater weight loss and health benefits than older drugs. However, access is currently limited by cost and insurance coverage. Discuss these options with your doctor, focusing on how treating multiple complications might justify the expense.

Unimolecular dual-agonists targeting GLP-1 and GIP receptors (e.g., tirzepatide) provide superior glycemic control and weight loss compared to GLP-1 receptor agonists alone by leveraging additive insulinotropic effects and distinct metabolic pathways.

If you have Type 2 Diabetes and struggle with weight, dual-agonist medications (like tirzepatide) may offer better blood sugar control and weight loss than older GLP-1 drugs. These medications work by mimicking gut hormones to boost insulin, reduce appetite, and increase energy expenditure. While they are injections and may cause temporary nausea, the clinical benefits for metabolic health are significant. Consult your doctor to see if this advanced therapy is appropriate for your specific health profile.

Lifestyle interventions (diet and physical activity) improve cardiometabolic risk through mechanisms independent of weight loss, primarily by reducing visceral and ectopic fat and improving metabolic markers.

Do not focus on the scale. Focus on improving diet quality and increasing physical activity. These actions will reduce visceral fat and improve metabolic markers (blood pressure, lipids, glucose) even if your total weight doesn't change much. This is the most effective way to reduce cardiovascular risk.

GLP-1 receptor agonists (GLP-1RAs) effectively manage type 2 diabetes and obesity by mimicking endogenous GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, and promote satiety through delayed gastric emptying and hypothalamic signaling.

GLP-1 receptor agonists are a proven treatment for Type 2 Diabetes and obesity. They work by mimicking a natural hormone to help your pancreas release insulin when needed, stop the release of sugar-storing hormones, and make you feel full faster. This leads to better blood sugar control and weight loss. While they are effective, they require injections, which can be a barrier for some patients.

GLP-1 receptor agonists induce significant fat mass loss with a non-significant or significantly smaller reduction in muscle mass, resulting in muscle mass accounting for less than 20% of total weight loss.

If you are taking a GLP-1 medication like Ozempic or Wegovy, your body is prioritizing fat loss over muscle loss. While you may lose a small amount of muscle, it is a minor fraction of your total weight loss (under 20%). Focus on maintaining strength through resistance training to preserve the muscle you have, but do not let fear of muscle loss stop you from using effective weight management tools.

Excessive fructose intake disrupts gut microbiota, reduces beneficial butyrate-producing bacteria, and downregulates tight junction proteins (ZO-1, Claudin-1, occludin), leading to increased intestinal permeability, endotoxemia, and obesity.

Excessive fructose, especially from syrup, damages your gut lining by reducing beneficial bacteria and tight junction proteins, leading to 'leaky gut' and inflammation. While moderate natural fructose from fruit is likely safe, avoid excessive fructose syrup to protect your gut and weight.

Protein intake in indoor team sports is the macronutrient most likely to meet official recommendations, with roughly 35.7% of studies showing compliance, though non-compliance is split evenly between under- and over-consumption.

You are more likely to hit your protein targets than your carb or energy targets, but you are still at risk of under-eating protein. Ensure you are eating enough protein to support recovery, but be aware that half of athletes in these studies under-consume it.

Resistance-trained individuals achieve similar quadriceps muscle hypertrophy after eight weeks of resistance training when terminating sets with 1-2 repetitions in reserve (RIR) compared to terminating sets at momentary muscular failure.

If you are experienced with resistance training, you do not need to train to absolute failure on every set to build muscle. Stopping your sets with 1-2 reps left in the tank (RIR) produces the same muscle growth as going to failure over an 8-week period. This approach likely allows you to recover faster and maintain better form, as failure training induces significantly higher acute fatigue and repetition loss.

GLP-1 receptor agonists (GLP-1RAs) and dual/triple incretin agonists produce clinically relevant hepatic improvements in patients with metabolic dysfunction-associated steatohepatitis (MASH), including MASH resolution, liver fat reduction, and prevention of fibrosis worsening.

If you have MASH or MASLD, especially with obesity or type 2 diabetes, GLP-1 receptor agonists (like semaglutide or tirzepatide) are a valuable treatment option. They not only help with weight and blood sugar but also directly improve liver health by reducing fat and inflammation. While lifestyle changes remain important, these medications can help achieve the necessary weight loss (7-10%) if you struggle to do so alone. Discuss these options with your gastroenterologist.

Among GLP-1 receptor agonists, tirzepatide induces the greatest reduction in body mass index (BMI), while orforglipron demonstrates the strongest benefit in lowering systolic blood pressure.

Not all GLP-1 drugs are equal for every health goal. If your primary concern is significant weight loss, tirzepatide shows the greatest BMI reduction in this analysis. If high blood pressure is the main issue, orforglipron showed the strongest blood pressure-lowering effect. Consult your doctor to choose the agent that best targets your specific cardiometabolic risks.

GLP-1 receptor agonist therapies significantly reduce C-reactive protein (CRP) levels, with semaglutide showing the most efficacious reduction compared to other agents.

GLP-1 therapies also help reduce systemic inflammation, as measured by C-reactive protein (CRP). Semaglutide was found to be particularly effective at lowering CRP levels, which may contribute to its cardiovascular benefits.

GLP-1 receptor agonists (specifically liraglutide) significantly reduce body weight and improve cardiometabolic risk factors (BMI, fasting plasma glucose, lipid profile) in obese or overweight individuals with psychotic disorders treated with antipsychotic drugs.

For patients with psychotic disorders on antipsychotics who struggle with obesity, GLP-1 receptor agonists (especially liraglutide) are a proven, effective treatment for weight loss and improving metabolic health. They significantly reduce body weight, BMI, and improve blood sugar and lipid levels without increasing the risk of stopping treatment compared to standard care. Liraglutide appears more effective than exenatide for weight loss in this group.